Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.

Current treatment options in oncology - 1 Aug 2023

Janssens Katleen, Lambrechts Chinouk, Geerinckx Barbara, Op de Beeck Ken, Van Camp Guy, Oliveres Helena, Prenen Hans, Vandamme Timon, Peeters Marc

Abstract excerpt

OPINION STATEMENT: One of the great challenges in digestive oncology is choosing the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Even though the RAS genes and accompanying pathway were identified decades ago and extensive knowledge exists on their role in carcinogenesis, it has proven challenging to translate these insights into new therapies and clinical benefit for patients. However,...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal
Colonic Neoplasms
Colorectal Neoplasms
ErbB Receptors
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins p21(ras)

Rectal Neoplasms

Source

Identifiers

PMID: 37212934
DOI: 10.1007/s11864-023-01095-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.PMID 37212934Read ↗

Strategies to tackle RAS-mutated metastatic colorectal cancer.Semantic proximity Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Targeting KRASG12C in colorectal cancer: the beginning of a new era.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.Semantic proximity Read ↗

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?Semantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

Metastatic colorectal cancer: current state and future directions.Semantic proximity Read ↗

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.